ArticleAnales del sistema sanitario de Navarra2026
[Subacute meningoencephalitis following intravesical BCG instillation immunotherapy].
Article in Anales del sistema sanitario de Navarra, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravesical instillation of Bacillus Calmette-Guérin (BCG), a live attenuated strain of Mycobacterium bovis, is the standard adjuvant treatment following transurethral resection of intermediate- and high-risk non-muscle-invasive urothelial carcinoma. Its therapeutic effect relies on intense local immune activation, reducing recurrence and progression rates and thereby improving patient outcomesand quality of life. Although generally well tolerated, both local and systemic infections and inflammatory complications may occur. We report a case of central nervous system BCG dissemination following intravesical BCG immunotherapy. The insidious onset and non-specific neurological manifestations complicated the diagnostic process and delayed the initiation of appropriate treatment. This case highlights the importance of thorough medical history assessment and maintaining a high index of suspicion in patients presenting neurological symptoms after intravesical BCG therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.